HSI1 27,051.16 +124.61 55.10B
HSCEI1 10,689.86 +76.23 13.86B
Back    Zoom +    Zoom - Block Traded
CSPC PHARMA 'Epirubicin Hydrochloride Liposome Injection' Approved for Clinical Trials in China
2019-10-22 17:04:16
CSPC PHARMA (01093.HK) announced that “Epirubicin Hydrochloride Liposome Injection” developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.*, a subsidiary of the Company, was granted approval by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

AAStocks Financial News
Web Site: www.aastocks.com